Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Shares Sold by Creative Planning

Creative Planning cut its holdings in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) by 10.1% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 25,409 shares of the biotechnology company’s stock after selling 2,867 shares during the period. Creative Planning’s holdings in Arrowhead Pharmaceuticals were worth $492,000 at the end of the most recent quarter.

Other large investors have also made changes to their positions in the company. Vanguard Group Inc. increased its position in shares of Arrowhead Pharmaceuticals by 16.2% during the first quarter. Vanguard Group Inc. now owns 12,404,050 shares of the biotechnology company’s stock worth $354,756,000 after purchasing an additional 1,731,974 shares in the last quarter. Avoro Capital Advisors LLC increased its position in shares of Arrowhead Pharmaceuticals by 3.9% during the second quarter. Avoro Capital Advisors LLC now owns 8,888,888 shares of the biotechnology company’s stock worth $231,022,000 after purchasing an additional 333,333 shares in the last quarter. American International Group Inc. increased its position in shares of Arrowhead Pharmaceuticals by 13.4% during the first quarter. American International Group Inc. now owns 220,217 shares of the biotechnology company’s stock worth $6,298,000 after purchasing an additional 26,009 shares in the last quarter. Susquehanna Fundamental Investments LLC acquired a new position in shares of Arrowhead Pharmaceuticals during the first quarter worth $3,663,000. Finally, Seven Eight Capital LP increased its position in shares of Arrowhead Pharmaceuticals by 592.3% during the first quarter. Seven Eight Capital LP now owns 75,224 shares of the biotechnology company’s stock worth $2,151,000 after purchasing an additional 64,358 shares in the last quarter. 62.61% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on ARWR shares. Piper Sandler reissued an “overweight” rating and issued a $62.00 target price on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, October 8th. HC Wainwright reissued a “buy” rating and issued a $60.00 target price on shares of Arrowhead Pharmaceuticals in a research report on Friday, October 11th. B. Riley reissued a “buy” rating and issued a $55.00 target price on shares of Arrowhead Pharmaceuticals in a research report on Monday, August 12th. Chardan Capital reissued a “buy” rating and issued a $60.00 target price on shares of Arrowhead Pharmaceuticals in a research report on Wednesday, July 17th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Arrowhead Pharmaceuticals in a research report on Monday, September 9th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and seven have assigned a buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $45.33.

Arrowhead Pharmaceuticals Stock Performance

NASDAQ:ARWR opened at $21.34 on Thursday. Arrowhead Pharmaceuticals, Inc. has a one year low of $17.05 and a one year high of $39.83. The firm has a market cap of $2.65 billion, a price-to-earnings ratio of -4.57 and a beta of 0.93. The firm’s fifty day moving average is $20.43 and its two-hundred day moving average is $23.51.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last posted its earnings results on Thursday, August 8th. The biotechnology company reported ($1.38) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.58) by ($0.80). During the same period last year, the firm earned ($0.96) EPS. The firm’s revenue was down 100.0% on a year-over-year basis. As a group, equities research analysts predict that Arrowhead Pharmaceuticals, Inc. will post -4.31 earnings per share for the current fiscal year.

Arrowhead Pharmaceuticals Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.